Bisphosphonate-based molecules as potential new antiparasitic drugs

Detalhes bibliográficos
Autor(a) principal: Branco Santos, Joice Castelo
Data de Publicação: 2020
Outros Autores: de Melo, Jonathas Alves, Maheshwari, Sweta, de Medeiros, Wendy Marina Toscano Queiroz, de Freitas Oliveira, Johny Wysllas, Moreno, Cláudia Jassica, Mario Amzel, L., Gabelli, Sandra B., Sousa Silva, Marcelo
Tipo de documento: Outros
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/116627
Resumo: Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.
id RCAP_708da13fadbcb7c4c86f42673ba86997
oai_identifier_str oai:run.unl.pt:10362/116627
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Bisphosphonate-based molecules as potential new antiparasitic drugsBisphosphonateChagas diseaseFarnesyl pyrosphosphate synthaseLeishmaniasisNeglected tropical diseasesChemistry (miscellaneous)Molecular MedicinePharmaceutical ScienceDrug DiscoveryParasitologySDG 3 - Good Health and Well-beingNeglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.Instituto de Higiene e Medicina Tropical (IHMT)Global Health and Tropical Medicine (GHTM)Vector borne diseases and pathogens (VBD)RUNBranco Santos, Joice Castelode Melo, Jonathas AlvesMaheshwari, Swetade Medeiros, Wendy Marina Toscano Queirozde Freitas Oliveira, Johny WysllasMoreno, Cláudia JassicaMario Amzel, L.Gabelli, Sandra B.Sousa Silva, Marcelo2021-05-01T22:52:53Z2020-06-032020-06-03T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other20application/pdfhttp://hdl.handle.net/10362/116627engPURE: 26669253https://doi.org/10.3390/molecules25112602info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:52:30Zoai:run.unl.pt:10362/116627Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:52:30Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Bisphosphonate-based molecules as potential new antiparasitic drugs
title Bisphosphonate-based molecules as potential new antiparasitic drugs
spellingShingle Bisphosphonate-based molecules as potential new antiparasitic drugs
Branco Santos, Joice Castelo
Bisphosphonate
Chagas disease
Farnesyl pyrosphosphate synthase
Leishmaniasis
Neglected tropical diseases
Chemistry (miscellaneous)
Molecular Medicine
Pharmaceutical Science
Drug Discovery
Parasitology
SDG 3 - Good Health and Well-being
title_short Bisphosphonate-based molecules as potential new antiparasitic drugs
title_full Bisphosphonate-based molecules as potential new antiparasitic drugs
title_fullStr Bisphosphonate-based molecules as potential new antiparasitic drugs
title_full_unstemmed Bisphosphonate-based molecules as potential new antiparasitic drugs
title_sort Bisphosphonate-based molecules as potential new antiparasitic drugs
author Branco Santos, Joice Castelo
author_facet Branco Santos, Joice Castelo
de Melo, Jonathas Alves
Maheshwari, Sweta
de Medeiros, Wendy Marina Toscano Queiroz
de Freitas Oliveira, Johny Wysllas
Moreno, Cláudia Jassica
Mario Amzel, L.
Gabelli, Sandra B.
Sousa Silva, Marcelo
author_role author
author2 de Melo, Jonathas Alves
Maheshwari, Sweta
de Medeiros, Wendy Marina Toscano Queiroz
de Freitas Oliveira, Johny Wysllas
Moreno, Cláudia Jassica
Mario Amzel, L.
Gabelli, Sandra B.
Sousa Silva, Marcelo
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Higiene e Medicina Tropical (IHMT)
Global Health and Tropical Medicine (GHTM)
Vector borne diseases and pathogens (VBD)
RUN
dc.contributor.author.fl_str_mv Branco Santos, Joice Castelo
de Melo, Jonathas Alves
Maheshwari, Sweta
de Medeiros, Wendy Marina Toscano Queiroz
de Freitas Oliveira, Johny Wysllas
Moreno, Cláudia Jassica
Mario Amzel, L.
Gabelli, Sandra B.
Sousa Silva, Marcelo
dc.subject.por.fl_str_mv Bisphosphonate
Chagas disease
Farnesyl pyrosphosphate synthase
Leishmaniasis
Neglected tropical diseases
Chemistry (miscellaneous)
Molecular Medicine
Pharmaceutical Science
Drug Discovery
Parasitology
SDG 3 - Good Health and Well-being
topic Bisphosphonate
Chagas disease
Farnesyl pyrosphosphate synthase
Leishmaniasis
Neglected tropical diseases
Chemistry (miscellaneous)
Molecular Medicine
Pharmaceutical Science
Drug Discovery
Parasitology
SDG 3 - Good Health and Well-being
description Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-03
2020-06-03T00:00:00Z
2021-05-01T22:52:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/116627
url http://hdl.handle.net/10362/116627
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PURE: 26669253
https://doi.org/10.3390/molecules25112602
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 20
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545794535817216